Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
Immunocore Holdings plc - American Depositary Shares (IMCR)
Company Research
Source: GlobeNewswire
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress Data from Phase 1 dose escalation trial shows IMC-F106C, a PRAME×CD3 ImmTAC, activates T cells and is well tolerated Durable RECIST responses and reduction in circulating tumor DNA (ctDNA) observed across multiple solid tumors Four expansion arms enrolling in cutaneous melanoma, ovarian, lung, and endometrial cancers Company to host a live webcast and conference call today at 12:30 PM EDT / 6:30 PM CEST (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 September 2022) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, has released today initial Phase 1 data for the first off-the-shelf ImmTAC® targeting PRAME, demon
Show less
Read more
Impact Snapshot
Event Time:
IMCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMCR alerts
High impacting Immunocore Holdings plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMCR
News
- Immunocore Holdings plc (NASDAQ: IMCR) had its price target raised by analysts at JPMorgan Chase & Co. from $60.00 to $70.00. They now have an "overweight" rating on the stock.MarketBeat
- Immunocore Holdings plc (NASDAQ: IMCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.MarketBeat
- Immunocore presented two posters at CROI 2024 [Yahoo! Finance]Yahoo! Finance
- Immunocore presented two posters at CROI 2024GlobeNewswire
- Immunocore Holdings plc (NASDAQ: IMCR) had its price target raised by analysts at Mizuho from $86.00 to $90.00. They now have a "buy" rating on the stock.MarketBeat
IMCR
Earnings
- 2/28/24 - Miss
IMCR
Sec Filings
- 3/21/24 - Form S-8
- 3/21/24 - Form S-3ASR
- 3/11/24 - Form SC
- IMCR's page on the SEC website